NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Verastem, Inc. ("Verastem" or the "Company") (NASDAQ:VSTM) on behalf of Verastem stockholders. Our investigation concerns whether Verastem has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On May 23, 2024, Verastem issued a press release "announc[ing] the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus ...